1. Interleukin-17A (IL-17A): A silent amplifier of COVID-19
- Author
-
Gian Marco Casillo, Giovanna Ambrosini, Luisa Costa, Francesco Maione, Cristian Salvatore, Federica Raucci, Raffaele Scarpa, Mariarosaria Bucci, Francesco Caso, Maione, Francesco, Casillo, GIAN MARCO, Raucci, Federica, Salvatore, Cristian, Ambrosini, Giovanna, Costa, Luisa, Scarpa, Raffaele, Caso, Francesco, and Bucci, Mariarosaria.
- Subjects
MAIT, mucosal-associated invariant T ,medicine.medical_treatment ,VEGF, Vascular endothelial growth factor ,GRO-α, growth-regulated oncogene-α ,ICAM-1, intercellular adhesion molecule-1 ,CD99, cluster of differentiation 99 ,SARS-CoV-2, severe acute respiratory syndrome Coronavirus 2 ,Cytokine storm ,Systemic inflammation ,TNF-α, tumour necrosis factor-α ,Severity of Illness Index ,PDGF, platelet-derived growth factor ,Drug Discovery ,PMNs, polymorphonuclear cells ,IL-17A ,IL-, interleukin ,IP-10, Interferon-inducible protein-10 ,COVID-19, Coronavirus disease 2019 ,Interleukin-17 ,General Medicine ,MCP-1, monocyte chemoattractant protein-1 ,CRS, cytokine release syndrome ,PECAM-1, platelet endothelial cell adhesion molecule-1 ,Cytokine ,Disease Progression ,G-CSF, granulocyte-colony stimulating factor ,Immunotherapy ,Th17 ,Interleukin 17 ,Inflammation Mediators ,medicine.symptom ,GM-CSF, granulocyte-macrophage colony-stimulating factor ,Cytokine Release Syndrome ,ILC3s, innate lymphoid cells (ILC3s) ,NK, natural killer ,Coronavirus disease 2019 (COVID-19) ,Cytokine storm COVID-19 IL-17A Immunotherapy Th17 ,RM1-950 ,Article ,IL-R, Interleukin- Receptor ,Immune system ,medicine ,Humans ,ARDS, acute respiratory distress syndrome ,MIP-2, macrophage inflammatory protein-2 ,Th, T-helper ,Pharmacology ,MMP-, matrix metalloproteinase ,business.industry ,COVID-19 ,IFN-γ, Interferon-γ ,medicine.disease ,COVID-19 Drug Treatment ,Pneumonia ,Immunology ,Therapeutics. Pharmacology ,business ,Biomarkers - Abstract
One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. Emerging evidence has identified a potential link between elevated interleukin-17A (IL-17A) levels and disease severity and progression. Considering that per se, IL-17A can activate several inflammatory pathways, it is plausible to hypothesize an involvement of this cytokine in COVID-19 clinical outcomes. Thus, IL-17A could represent a marker of disease progression and/or a target to develop therapeutic strategies. This hypothesis paper aims to propose this “unique” cytokine as a silent amplifier of the COVID-19 immune response and (potentially) related therapy., Graphical Abstract ga1
- Published
- 2021
- Full Text
- View/download PDF